evotec oai ag first quarter report 2004 dear shareholders for further information please contact anne hennecke investor relations corporate communications 49 0 40 560 81 286 333 fax evotecoai com schnackenburgallee 114 d 22525 hamburg www overall continues to progress in line with the forecasts as communicated february respect our q1 results there are three key comments 1 revenues were 19 lower than 2003 this decline is due general difficult market conditions adverse currency effects and a major single item sale amount of approximately eur 3 million going forward we believe that will benefit from upturn observing contract research outsourcing already resulting significant order intake strong deal flow 2 discovery development services has been highlighted by new contracts panacos us rib x pharmaceuticals toray japan fujisawa which have contributed positively towards building book made substantial programs division dpd strategy
